Your browser doesn't support javascript.
loading
Hypoallergenicity assessment of an extensively hydrolyzed whey-protein formula in cow's milk allergic infants.
Dahdah, Lamia; Roelofs, Mieke; Knipping, Karen; de Vries, Esther; Rijnierse, Anneke; Garssen, Johan; Brand, Paul L P; Fiocchi, Alessandro.
Afiliação
  • Dahdah L; Allergy Unit, Pediatric University Department, Bambino Gesù Children's Hospital, Rome, Italy.
  • Roelofs M; Danone Nutricia Research, Utrecht, the Netherlands.
  • Knipping K; Danone Nutricia Research, Utrecht, the Netherlands.
  • de Vries E; Faculty of Science, Department of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • Rijnierse A; Department of Pediatrics, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
  • Garssen J; Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, the Netherlands.
  • Brand PLP; Danone Nutricia Research, Utrecht, the Netherlands.
  • Fiocchi A; Danone Nutricia Research, Utrecht, the Netherlands.
Pediatr Allergy Immunol ; 33(6): e13814, 2022 06.
Article em En | MEDLINE | ID: mdl-35754130
ABSTRACT

BACKGROUND:

Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA).

OBJECTIVES:

Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey-protein formula (eHWF) in CMA children were assessed.

METHODS:

In this prospective, randomized, international, multi-center study (Trial NL3889), 34 children with confirmed CMA (74% IgE-mediated) underwent a double-blind, placebo-controlled food challenge (DBPCFC) with an eHWF developed with non-porcine enzymes, supplemented with prebiotic short-chain galacto- and long-chain fructo-oligosaccharides (0.8 g/L, ratio 91), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participated in a 7-day open food challenge with this eHWF. Anthropometrics and GI tolerability were assessed in an optional 16-weeks follow-up.

RESULTS:

Of the 34 children who started the DBPCFC with the eHWF, 25 subjects (19 boys, mean age 61 weeks, 18 with IgE-mediated CMA) completed the DBPCFC and 7-day open challenge without major protocol deviations and tested negative at both challenges. One child experienced a late moderate eczematous allergic reaction in the optional follow-up period, indicating the need for close monitoring of subjects starting new formula. Weight and length gain followed the World Health Organization growth curves. Changes in frequency and consistency of stools upon test formula intake were transient.

CONCLUSIONS:

The newly developed eHWF is a suitable option in CMA treatment as all subjects tolerated the product. This result is in line with the international criteria for hypoallergenicity (American Academy of Pediatrics) that state that more than 90% of CMA children must tolerate the formula. Use of the formula is also associated with normal growth curves and GI tolerability. TRIAL REGISTRATION Trial NL3889, https//www.trialregister.nl/trial/3889.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Leite / Leite Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Animals / Child / Female / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Leite / Leite Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Risk_factors_studies Limite: Animals / Child / Female / Humans / Infant Idioma: En Ano de publicação: 2022 Tipo de documento: Article